Market research
603811.SHG Zhejiang Cheng Yi Pharmaceutical Co., Ltd
SHG CNY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- 16.82
- Analyst target
- Not available
- Dividend yield
- 2.8%
- Beta
- 0.07
Profile
Company facts
- Exchange
- SHG
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CNE100002YC7
- Market cap
- 3B
- P/E ratio
- 16.82
- Analyst target
- Not available
- Dividend yield
- 2.8%
- Beta
- 0.07
About
About Zhejiang Cheng Yi Pharmaceutical Co., Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, capsules, tablets, traditional Chinese medicines, preparations, and intermediates; and joint-related drugs, diuretics and antihypertensive drugs, antiviral drugs, antitumor drugs, vitamins, and sedative and brain-boosting drugs, as well as other health products and medical instruments. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is based in Shanghai, China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 603811.SHG discussion.
5 years, 5 months ago
Zhejiang Cheng Yi Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 2.0% above its 200 day moving average.
From a valuation standpoint, the stock is 21.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.6.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd's total revenue rose by 13.7% to $182M since the same quarter in the previous year.
Its net income has increased by 27.8% to $39M since the same quarter in the previous year.
Finally, its free cash flow fell by 133.6% to $-10M since the same quarter in the previous year.
Based on the above factors, Zhejiang Cheng Yi Pharmaceutical Co., Ltd gets an overall score of 4/5.